David Sinclair launches first oral reprogramming bid, after Life Biosciences dosed a glaucoma patient

Earlier this week, Life Biosciences announced it had dosed its first volunteer. The participant, who has glaucoma, received an experimental treatment injected straight into their eyeball, with the goal of regenerating healthy nerves in the eye to treat a disease that can cause vision loss.

And that matters because the company is not treating this as a one-off eye problem. David Sinclair, the chairman and cofounder behind the trial, is openly aiming higher. If the treatment can reverse glaucoma, he hopes it can pave the way for similar approaches to other age-related diseases, and maybe even aging itself. That big, ambitious framing is exactly why the most buzzy approach in longevity right now is called “reprogramming”: pushing adult cells toward a younger state.

To understand why investors are paying attention, you have to see the field’s last few years as a kind of hype-and-rotation cycle. Aging biology is messy. In 2013, one influential paper laid out nine “hallmarks of aging,” and researchers spent years trying to intervene on them one by one. Some targets rose fast, then cooled off. Telomere attrition is the clean example. Telomeres are DNA sequences at chromosome ends, like the plastic tips on shoelaces that keep DNA ends from fraying. When cells divide, telomeres shorten until the DNA becomes vulnerable to damage. Telomere shortening was once linked to age-related diseases in the heart and brain, and shortened telomeres were treated as a sign of premature aging.

Then the spotlight shifted. In 2017, Liz Parrish, CEO of BioViva, injected herself with an experimental gene therapy she hoped would lengthen her telomeres. The excitement faded afterward, even as research continued. The community moved on to cellular senescence: cells that stop dividing but do not die, instead entering a “zombie” state that secretes chemicals that can drive harmful inflammation. The idea sounded almost too neat. If senescent cells accumulate in many organs and contribute to age-related damage, why not periodically clear them out?

In mice, a senolytic strategy did look promising. A team of scientists took that approach in 2011 and reported delayed onset of age-related conditions like cataracts and hunchback, and the treated mice even looked younger. But the human translation stumbled. Unity Biotechnology trialed a similar approach in people with osteoarthritis and an age-related eye condition in the late 2010s and early 2020s. Results were disappointing, and the company laid off every employee in May last year and has shuttered entirely. That experience did not prove senolytics never work, but it did change sentiment. It also helps explain why the current “reprogramming” wave feels more like a fresh pitch than a repeat of old promises.

Reprogramming is rooted in a Nobel Prize-winning discovery: four genetic factors can turn an adult cell into a stem cell. In principle, that stem-like state can then be nudged into becoming many different cell types. In mice, multiple studies suggest the approach could help wind back the clock. The MIT Technology Review article notes improvements in tissue healing, restored vision, and even improved learning and memory. Those are exactly the kinds of outcomes that attract both scientific attention and boardroom attention.

Follow the money, and you see why. Funding for reprogramming has poured in alongside the science. In 2021, Antonio Regalado reported the founding of Altos Labs to pursue reprogramming for rejuvenation. Altos was funded by billionaire Yuri Milner, reportedly along with Jeff Bezos and others, totaling $3 billion, described as a previously unheard-of figure for a biotech startup. Other well-funded companies have followed. Retro Biosciences is pursuing reprogramming (among other approaches) with an effort to add 10 years of healthy life to human lifespans, with its launch supported by $180 million from OpenAI’s Sam Altman. Retro announced a valuation of $1.8 billion last month.

NewLimit, another billionaire-backed biotech exploring reprogramming, says it has promising results from mouse research and plans a trial of a drug designed to rejuvenate the liver in people next year. The company announced it raised $435 million last week toward reaching that goal, among others. Life Biosciences itself secured $80 million to support its research, and the eye trial is now officially underway.

What Sinclair is doing next connects the trial to the broader pitch. Earlier this week, Sinclair told Antonio that he plans to test a “highly, highly confidential” oral reprogramming drug as part of a $101 million competition organized by the XPrize Foundation. That is an important detail for decision-makers because it signals an intent to develop reprogramming not just as a surgical or localized therapy, but as a scalable intervention platform.

But there’s a reason the MIT Technology Review piece puts a giant caution sign next to all the excitement. The article says researchers still do not know if reprogramming will work, and it comes with risks. This creates a strategic dilemma for executives across biotech, pharma, and investment: the upside is enormous, but the downside is real enough that past approaches have already burned companies and careers. The question now is whether reprogramming delivers a rejuvenation drug within reach, or whether the next research trend simply moves on to the next promising biological lever. For boards and capital allocators, the second-order stakes are clear: when the field’s attention swings, the winners will be the teams that can translate mouse signals into safe, effective human biology without turning ambition into a funding bonfire.